Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554041 | 0.95 | ALDH1A1 (0.64) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL5253878 | 0.93 | ALDH1A1 (0.62) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL2655008 | 0.93 | ALDH1A1 (0.62) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL2655484 | 0.89 | ALDH1A1 (0.70) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL10360804 | 0.87 | ALDH1A1 (0.77) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL1789262 | 0.86 | ALDH1A1 (0.66) | ALDH1A1LMNADHODHKDM4ETSHR | |
| SCHEMBL385826 | 0.85 | ALDH1A1 (0.64) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL5734169 | 0.85 | ALDH1A1 (0.64) | ALDH1A1LMNADHODHKDM4EGLA | |
| SCHEMBL28106654 | 0.85 | ALDH1A1 (0.64) | ALDH1A1LMNADHODHTSHRHSD17B10 | |
| SCHEMBL6621914 | 0.85 | ALDH1A1 (0.64) | ALDH1A1LMNADHODHKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110157251-B | Curing agent composition and coating composition comprising same | ＫＣＣ公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-2802557-B1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9187411-B2 | Leukotriene B4 antagonist compound | ELI LILLY AND COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY | 2014-11-20 | — | — | US | disclosed |
| EP-2802557-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | Eli Lilly and Company (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106238-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | ELI LILLY AND COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1541559-A1 | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| US-6133446-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0737189-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | UPJOHN CO (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5877317-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| CN-1145619-A | Substituted pyridine leukotriene B4 antagonists | HOFFMANN LA ROCHE (CH) | 1997-03-19 | — | — | CN | disclosed |
| EP-0755381-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B 4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-29 | — | — | EP | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995028386-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343151-A1 | LEUKOTRIENE B4 ANTAGONIST COMPOUND | LTB4R2, LTB4R, LTA4H | ALDH1A1 2170/4885LMNA 755/4885DHODH 1047/4885 |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | MYLK, MYLK2, MYL12A | ALDH1A1 2534/4885LMNA 178/4885DHODH 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.